Skip to main content

Table 3 Retrospective comparison in 11 patients

From: From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

New ID

Cancer

Number of SNVs

Number of CNVs

MASTER report

MTB report

Gene

Drug

Number of results

Match

Match level

Drug support

MASTER-01

Breast cancer metastasis

104

3410

BRCA1/2 deletions

PARP inhibitors

43

Yes

B2

11.6%

RAF1, PDGFRA amplifications

Sorafenib

 

Yes

B3

4.6%

FGF1 (T8N)

FGFR inhibitor

 

Yes

2.3%

MASTER-02

Pancreatic adenocarcinoma

49

1528

KRAS (G12D)

92

MASTER-03

Leiomyosarcoma of the retroperitoneum

31

3181

PTPRJ deletion

Pazopanib

12

No

CDK12 + BRCA2 deletions

Cisplatin

 

Yes

B2

50%

MASTER-04

Ovarian carcinoma

98

3385

TSC2 (R505X)

mTOR inhibitor

56

Yes

B2

12.5%

MASTER-05

Myxoid liposarcoma

11

72

PIK3CA (C420R) + PTEN (R130G)

mTOR inhibitor

75

Yes

B2

9.3%

 

AKT inhibitor

 

Yes

B2

2.4%

 

PI3K inhibitor

 

Yes

B2

32%

MASTER-06

Neuroendocrine tumor

2703

2060

MTOR (P2490L, G332R)

mTOR inhibitor

89

Yes

B2

16.8%

PTPN12 (S509 N, G523S)

Lapatinib, erlotinib, imatinib, desatinib

 

No

KIT (A837T)

Imatinib, desatinib

 

Yes

B3

1.1%

LCK (P74L)

Desatinib

 

No

MASTER-07

Neuroendocrine tumor

645

941

ERBB3 (V104 M), RAF1 (S259P), MTOR (E1485G)

mTOR inhibitor

40

Yes

A2

12.5%

MASTER-08

Cholangiocarcinoma

28

1001

ERRFI1 (R199X)

Erlotinib

17

Yes

0.58%

MASTER-09

Clear cell sarcoma

11

1

NTRK3 (R116W)

Lestaurtinib, midostaurin

3

No

MASTER-10

Histiocytic sarcoma

7

5

BRAF (F595 L) + HRAS (Q61R)

MEK inhibitor

11

Yes

B2

33.3%

sorafenib (multi TKi)

 

Yes

B3

5.5%

MASTER-11

Pulmonary adenocarcinoma

70

146

EGFR (p.745-750del)

Erlotinib

54

Yes

B2

22.2%

  1. Actionable variants discussed by experts as part of the NCT MASTER trial (MASTER report) were compared to actionable variants reported by our method (MTB report)